title: High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.
abstract: OBJECTIVE
  To report the rates of grade IV adverse events and hepatitis C virus (HCV) treatment discontinuation associated with the use of telaprevir, pegylated interferon, and ribavirin.
  
  
  METHODS
  Retrospective cohort analysis.
  
  
  METHODS
  The study included patients coinfected with HIV and HCV who underwent HCV treatment in a clinic-based setting with telaprevir, pegylated interferon, and ribavirin. The United States of America National Institutes of Health Division of AIDS grading system was used to rate severity of adverse events.
  
  
  RESULTS
  Of the 24 consecutive patients treated for HCV using telaprevir/pegylated interferon/ribavirin, 50% (12/24) developed serious adverse events and 29% (7/24) discontinued HCV treatment due to adverse events, despite an intensive multidisciplinary monitoring approach.
  
  
  CONCLUSIONS
  In this HIV clinic-based experience, a high rate of grade IV adverse events and treatment discontinuations were observed associated with HCV telaprevir-based treatment. Careful consideration of the risks and benefits of telaprevir-based therapy should be undertaken, given prospects for interferon-sparing therapy in the near future.
authors.affiliation: aDepartment of Medicine, Owen Clinic bDivision of Infectious Diseases, Department of Medicine cSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, San Diego, California, USA.
authors.forename: Edward R
authors.initials: ER
authors.lastname: Cachay
authors.forename: David L
authors.initials: DL
authors.lastname: Wyles
authors.forename: Francesca J
authors.initials: FJ
authors.lastname: Torriani
authors.forename: Craig
authors.initials: C
authors.lastname: Ballard
authors.forename: Bradford
authors.initials: B
authors.lastname: Colwell
authors.forename: Jennifer C
authors.initials: JC
authors.lastname: Lin
authors.forename: Lucas
authors.initials: L
authors.lastname: Hill
authors.forename: William C
authors.initials: WC
authors.lastname: Mathews
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012720:Severity of Illness Index; D014481:United States / Q000453:epidemiology; D028761:Withholding Treatment
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D012254:Ribavirin; C486464:telaprevir